Pharavee Jaiprasart

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Emerson A. Lim, Michael T. Schweizer, Kim N. et al. · Clinical Genitourinary Cancer · 2023 · 58 citations · Full text

Medicine, Oncology, Pharmacology +17

Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis

Deepika Neelakantan, Samrita Dogra, Bharat Devapatla et al. · Molecular Cancer Research · 2019 · 32 citations · Full text

Medicine, Cancer Biology, Oncology +17

Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans

Xiling Jiang, Xi Chen, Pharavee Jaiprasart et al. · European Journal of Pharmaceutical Sciences · 2020 · 25 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Mark N. Stein, Armelle Vinceneux, Debbie Robbrecht et al. · Journal of Clinical Oncology · 2025 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

Emerson A. Lim, Michael T. Schweizer, Kim N. et al. · Journal of Clinical Oncology · 2022 · 16 citations

Medicine, Oncology, Pharmacology +17